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OBJECTIVES: To measure cost of care in cardiologic
departements for inpatients with decompensated, systolic
heart failure and to study major cost drivers. METHODS:
In 2000, a multicentric observational study was set up
within 8 cardiology departments in France. Patients over
18, hospitalized with decompensated systolic heart failure
(HF), and LVEF < 45% were prospectively included. Data
were collected up to ﬁnal discharge from the department.
Cost of lab tests, procedures, blood products and phar-
macy were extracted from ofﬁcial guidelines or public
hospital sources. Other patients’ stay ﬁxed costs, includ-
ing staff and overheads, were averaged from hospital
sources. Factorial analysis was performed on patients’
socio-demographic and clinical caracteristics. RESULTS:
Two hundred twenty-one patients were included, with
mean age 66 years, 62% male. Main diagnoses were coro-
nary heart disease (CHD): 48%, and dilated cardiomy-
opathy: 28%. Average length of stay (LOS) in cardiologic
departement was 12.4 days. Average total cost was €5770
(sd: €3975) for each patient. Factors linked to higher costs
were: transfert from an other department, emergency
admittance, new diagnosis, no previous treatment, and
ﬁrst hospitalization. Factorial analysis identiﬁed 3 clus-
ters: one cluster of elderly patients, mean age 77 years,
higher LVEF (36%), 60% previously known HF, two
clusters with younger patients: mean age 64 years, mainly
with CHD; patients in cluster 2 had 97% HF already
known and 88% former hospitalization, lower LVEF
(26%), whereas in cluster3 100% new diagnosis of HF,
high proportion of ICU stay. Hospitalization costs were
higher (p < 0.01) in cluster 3 (€6792) than in cluster 2
(€5692) or 1 (€5016), without difference in LOS. Main
cost difference was linked to invasive cardio-vascular pro-
cedures (€1177 in cluster 3, versus €266 in other clusters,
p < 0.001). CONCLUSION: Higher costs for patients
with decompensated heart failure were related to ﬁrst
hospitalization and new diagnosis, intensive cardiac pro-
cedures, mainly for coronary artery disease. Hospitaliza-
tion costs were lower for relapses.
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OBJECTIVE: To generate estimates of the cost-
effectiveness of combined ACE-inhibitor and calcium
antagonist therapy (Tarka) versus ACE-inhibitors (usual
care) in patients with heart failure after myocardial
infarction in the US health care setting. METHODS:
Markov process analysis techniques were used to model
the health eonomic outcomes. Data on probabilities of
clinical events were derived from clinical trial data and
other published literature; units of health care utilization
were derived from the literature and the HCUP database;
prices/tariffs were derived from ofﬁcial lists. Study per-
spective was that of the third party payer. RESULTS: An
analysis over the Tarka trial period shows that Tarka
decreases the costs from US$24,567 to US$19,907. The
mortality for Tarka is at least equal to usual care (1.96%
versus 2.04%) and consequently Tarka can be considered
dominant over usual care. Tarka remains cost saving over
a follow-up of 5 and 10 years. The cost saving are respec-
tively US$5120 and US$3642. The use of Tarka also leads
to substantial reductions in cumulative mortality, which
are respectively 9.4% and 11.7% over 5 and 10 years.
The lifetime model shows that the use of Tarka leads to
an incremental cost-effectiveness ratio of US$1730 per
life year gained. Probabilistic sensitivity analysis showed
that the probability is 55% that the incremental cost
effectiveness ratio of Tarka is less than US$5000 per life
year gained, while the incremental cost effectiveness ratio
will always be less than US$10,000. CONCLUSION: The
results showed that the favourable clinical beneﬁt of
Tarka results in positive short and long-term health eco-
nomic beneﬁts.
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OBJECTIVE: Pressure-based fractional ﬂow reserve
(FFR) is an invasive test for assessing the functional 
signiﬁcance of intermediate coronary stenoses. Previous
studies have found that FFR testing to guide percutaneous
coronary intervention (PCI) is cost-effective. In this study
we evaluate the impact of using drug-eluting stents (DES)
on this decision. METHODS: We developed a Markov
model to compare the long-term costs and outcomes of 2
strategies for patients with indeterminate coronary steno-
sis scheduled for PCI: 1) Universal PCI (UNIV) without
FFR testing, and 2) FFR testing followed by PCI only for
those with FFR < 0.75 (TEST). Base-case: 60-year-old
man under the optimistic assumption (for UNIV) that 
relative mortality reduction with revascularization is
independent of functional signiﬁcance. Data: long-term
clinical outcomes of PCI and medical management includ-
ing recurrence rates, disease progression, and quality of
life based on published literature. Based on ﬁxed effects
meta-analysis, we estimated that DES reduce clinical
restenosis rates by 79% compared with bare metal stents
(BMS). Perspective: societal. Discounting: 3% per year.
RESULTS: For the case of BMS, UNIV increased costs by
$2800/patient and improved outcome by 12 quality-
adjusted life days (QALD), yielding an incremental cost-
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effectiveness ratio (ICER) of $84,000 per quality-adjusted
life year (QALY) gained. When considering the beneﬁts
of DES, incremental costs increased to $3300 and beneﬁt
of UNIV increased to 18 QALDs, with an ICER of
$69,000/QALY. Results were similar for women and over
a broad age range (55–75 years). If we assumed that PCI
in functionally insigniﬁcant stenoses did not reduce long-
term mortality, the ICER for UNIV vs. TEST was >$1
million/QALY. CONCLUSIONS: Regardless of stent type
(BMS or DES), measuring FFR to guide the decision to
perform PCI leads to signiﬁcant cost savings. Even under
very optimistic assumptions regarding mortality beneﬁts
and restenosis rates for DES, universal stenting does not
appear to be cost-effective when compared to other well-
accepted interventions in health care.
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OBJECTIVE: The objective of this analysis is to assess
the cost and quality of life of patients treated for hyper-
cholesterolemia in Germany. METHODS: The following
analysis uses the baseline data assessed at the begin-
ning of the randomised controlled German ORBITAL
study, designed to determine the impact of a compliance-
enhancing program on long-term disease-related out-
comes and costs. More than 8000 patients with
hypercholesterolemia (HC) eligible for statin therapy
have been enrolled. At baseline patients completed a
detailed questionnaire. Health care resource use over 
the past 6 months, preceding enrolment, as well as quality
of life (SF-12, EQ-5D and EQ-VAS) was assessed.
RESULTS: A total of 2500 patients (mean age 61 ± 11
years, 44% female) were included in this analysis, 32%
were employed at the time of inclusion, 19% had a
history of myocardial infarction, 8% a history of stroke,
61% had hypertension and 28% diabetes. Disease-related
direct costs amounted to a mean of €655 per patient in
the six months period, indirect costs to €1495 per patient.
Direct costs included mainly costs for hospital stays
(€433), primary care consultations (€111), outpatient
therapeutic measures (€54), and rehabilitation (€43).
Indirect costs due to days off work amounted to €303,
due to early retirement to €1191. Mean quality of life
according to the EQ-5D was 0.81 (EQ-VAS 0.69). The
mean scores of the SF-12 were 47.60 (PCS) and 43.24
(MCS). CONCLUSIONS: Indirect costs due to a loss of
productivity contributed markedly to the disease-related
costs in patients with HC. The considerable economic
burden of HC indicates the need to assess long-term effec-




THROMBOLYSIS FOR THE TREATMENT OF
ACUTE MYOCARDIAL INFARCTION: A
SYSTEMATIC REVIEW OF THE LITERATURE
Boland A, Haycox AR, Mujita Mota R, Dundar Y, Bagust A,
Dickson R, Walley T
University of Liverpool, Liverpool, United Kingdom
OBJECTIVES: To carry out a systematic review of the lit-
erature comparing the cost-effectiveness of thrombolytic
agents currently available in the UK for treatment of AMI
in either a hospital or pre-hospital setting. The aim of 
this review was to identify economic evaluations that 
had been undertaken in the context of high quality ran-
domised controlled trials in order to inform UK NHS
decision-making. METHODS: The search included a
number of strategies. Search terms for electronic data-
bases (MEDLINE, EMBASE, HTA, DARE, NHS-EED,
Cochrane Trials Register) included a combination of
index terms and free word text. Using explicit, predeter-
mined criteria, two reviewers independently identiﬁed
studies for inclusion in the cost-effectiveness review
process. Quality assessment using the Drummond 10-
point checklist was also performed. RESULTS: No
studies in the pre-hospital setting met the inclusion crite-
ria. In the hospital setting, 107 papers were considered
for inclusion in the review and 8 met the inclusion crite-
ria. All of the studies justiﬁed their choice of comparator,
performed incremental cost-effectiveness analysis and
included relevant comparators. Authors in Europe
applied the results of the GUSTO I study to their own 
settings in an attempt to compare the cost-effectiveness
of alteplase versus streptokinase. Consequently, cost-
effectiveness ratios were expressed in several currencies,
a reﬂection of the international interest in the choice
between alteplase and streptokinase. Some studies did not
sufﬁciently explore the true cost of complications over the
patient’s lifetime, nor was this addressed fully by sensi-
tivity analysis. Only three studies considered issues that
can be addressed by cost-utility analyses. Overall the
studies were of good quality. CONCLUSIONS: Existing
economic evaluations are of limited value in determining
the relative cost-effectiveness of thrombolytic drugs in the
NHS. Published studies are almost all industry funded
and interpretation of results depends on whether one
accepts or rejects the assumption of superiority of
alteplase over streptokinase.
